Trial Profile

A Phase 1b Study of Pembrolizumab (KEYTRUDA) in Combination With REOLYSIN (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pelareorep (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions
Sponsors Oncolytics Biotech

06 Nov 2019 Results presented in the Oncolytics Biotech Media Release.
06 Nov 2019 Results assessing efficacy and safety of pembrolizumab in combination with pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma, published in the Clinical Cancer Research.
04 Jun 2019 Results of the immune analysis in peripheral blood for the prediction of response to pelareorep plus pembrolizumab in PDAC, presented at the 55th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com